Voyager Therapeutics (VYGR) Operating Leases (2019 - 2026)

Voyager Therapeutics has disclosed Operating Leases across 8 years of filings, most recently posting $27.2 million for Q1 2026.

• Operating Leases for Q1 2026 came in at $27.2 million, down 21.3% year-over-year; the trailing twelve-month figure through Mar 2026 was $27.2 million (down 21.3% YoY), and the FY2025 annual result was $28.7 million, down 21.48% from the prior year.
• Operating Leases came in at $27.2 million for Q1 2026 at Voyager Therapeutics, down from $28.7 million in the prior quarter.
• In the past five years, Operating Leases ranged from a high of $42.0 million in Q1 2024 to a low of $17.1 million in Q4 2023.
• The 5-year median for Operating Leases is $28.7 million (2025), against an average of $28.5 million.
• Across the five-year window, Operating Leases tumbled 47.45% in 2022 and surged 115.13% in 2024, its largest moves.
• Voyager Therapeutics' Operating Leases stood at $20.3 million in 2022, then decreased by 15.77% to $17.1 million in 2023, then surged by 113.52% to $36.5 million in 2024, then retreated by 21.48% to $28.7 million in 2025, then fell by 5.08% to $27.2 million in 2026.
• The last three Operating Leases figures came in at $27.2 million (Q1 2026), $28.7 million (Q4 2025), and $30.5 million (Q3 2025), per Business Quant data.